Tempest Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$3.12(as of Dec 5, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Tempest Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$3.12
Ticker SymbolTPST
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees24
CountyUSA
Market Cap$15.4M

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Tempest Therapeutics Inc In Our Stock Scanner

As of Dec 08, 2025
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Double BottomScan Type: Chart Pattern Scans
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.